Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-04-30

FDA Approved: EVRYSDI — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for EVRYSDI (risdiplam) from Genentech, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • EVRYSDI (risdiplam)

Snippet

SUPPL AP for EVRYSDI (RISDIPLAM)